NCT01068782 2026-02-25
Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
Exelixis
Phase 2 Terminated
Exelixis
National Institutes of Health Clinical Center (CC)
Day One Biopharmaceuticals, Inc.
Dartmouth-Hitchcock Medical Center
Day One Biopharmaceuticals, Inc.
Alaunos Therapeutics
University of Oklahoma